Does UnitedHealthcare Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and What to Do When You're Denied

Reviewed by FormBlends Medical Team · Last updated September 5, 2026 · 30 sources cited

Key Takeaways

• UnitedHealthcare's commercial policy effective September 1, 2026 covers Wegovy injection and tablet with prior authorization for patients 12 and older (over 16 for Wegovy HD) with a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity, used as an adjunct to lifestyle modification; the policy does not require a documented 3-to-6-month failure period
• Initial authorization is 5 months; renewal requires documented weight loss of at least 5 percent of baseline body weight plus continued lifestyle modification and then runs 12 months. No UnitedHealthcare denial rate is published, and the 40 percent figure printed here earlier has been removed
• Since July 1, 2026, Medicare enrollees, including UnitedHealthcare and AARP Part D and Medicare Advantage members, can get the Wegovy pen or pill for $50 a month through the Medicare GLP-1 Bridge if they meet its BMI criteria and do not have type 2 diabetes, sleep apnea or MASH (CMS, August 6, 2026)
• When a commercial plan covers Wegovy, the Novo Nordisk savings card lowers the copay to as little as $25 with maximum savings of $100 a month; if it does not, Novo Nordisk's self-pay price is $199 a month for a new patient's first two pen fills then $349, $399 for Wegovy HD, and $149 to $299 for the pill (seen September 4, 2026)

The short answer

As of September 5, 2026: UnitedHealthcare covers Wegovy for weight loss on commercial plans whose employer includes weight-loss drugs, with prior authorization under a policy effective September 1, 2026 that requires age 12 or older, a BMI of 30 or higher (or 27 with a comorbidity such as dyslipidemia, hypertension, type 2 diabetes or sleep apnea), and use alongside lifestyle modification; approval lasts 5 months and renews for 12 months at 5 percent weight loss. Self-funded employers can exclude it, in which case separate nonformulary criteria apply. For UnitedHealthcare and AARP Medicare members, the Medicare GLP-1 Bridge has covered the Wegovy pen and pill at $50 a month since July 1, 2026 for enrollees meeting obesity criteria without diabetes.

Table of contents

1. The coverage landscape: which UHC plans cover Wegovy and which don't
2. Prior authorization requirements: the exact criteria your provider must document
3. The denial pattern: why 40% of requests fail and how to avoid it
4. What most articles get wrong about Medicare coverage
5. The cost breakdown when coverage is approved
6. The manufacturer savings card: when it works and when UHC blocks it
7. Step therapy requirements: the medications you must try first
8. The appeal process: a working protocol for overturning denials
9. Compounded semaglutide as the coverage alternative
10. When to expect policy changes: the 2027 Medicare coverage expansion
11. UnitedHealthcare's Wegovy criteria (September 1, 2026)
12. Which UHC plan types require PA
13. UHC and AARP Medicare members: Wegovy for $50
14. Why your employer may have opted out
15. What you pay when UHC covers it, and when it does not
16. Wegovy pill and 1.5 mg under UHC
17. FAQ
18. Footer disclaimers

The coverage landscape: which UHC plans cover Wegovy and which don't

UnitedHealthcare operates multiple insurance products, and Wegovy coverage differs across each:

Plan type	Wegovy coverage	Prior auth required	Notes
UHC Commercial (employer-sponsored)	Yes, on most formularies	Yes	Coverage depends on employer plan design; some self-insured employers exclude all GLP-1s for weight loss
UHC Medicare Advantage with drug coverage	Yes, through the Medicare GLP-1 Bridge since July 1, 2026	Yes, at the first fill, decided within 72 hours	$50 a month; BMI 35 or higher, or 30 or 27 with specific conditions; no type 2 diabetes, OSA or MASH; runs through December 31, 2027
Traditional Medicare with a UHC or AARP Part D plan	Yes, through the same Medicare GLP-1 Bridge	Yes, at the first fill	The statutory exclusion still bars ordinary Part D coverage; the Bridge is a CMS demonstration outside the regular benefit (Medicare.gov)
UHC Medicaid (state-dependent)	Varies by state	Yes, where covered	13 states covered GLP-1s for obesity as of January 2026 (KFF); MassHealth ended coverage July 1, 2026 and Rhode Island ends it in October 2026
UHC Oxford (regional commercial)	Yes	Yes	Same criteria as national commercial plans

Correction, September 2026: an earlier version of this paragraph said Medicare Advantage plans could cover Wegovy while Part D could not. Both follow Part D drug rules, so neither covered Wegovy for weight loss on its own. What changed is the Medicare GLP-1 Bridge, which since July 1, 2026 covers the Wegovy pen and pill at $50 a month for eligible enrollees whether their drug coverage comes from a UHC Medicare Advantage plan or a standalone UHC or AARP Part D plan.

The employer plan design question matters more than most patients realize. UnitedHealthcare administers both fully insured plans (where UHC bears financial risk and sets the formulary) and self-insured plans (where the employer bears risk and can customize exclusions). A Fortune 500 company can choose to exclude all weight-loss medications even if UHC's standard formulary includes them. Your Summary of Benefits document, not UHC's public formulary, is the final authority.

Prior authorization requirements: the exact criteria your provider must document

When Wegovy is on formulary, UnitedHealthcare requires prior authorization. The criteria below are from UnitedHealthcare's Pharmacy Prior Authorization Notification for weight-loss drugs, effective September 1, 2026:

Clinical criteria (all must be met):

1. BMI threshold: BMI of 30 kg/m2 or higher (or, for pediatric patients, above the 95th percentile), OR BMI of 27 kg/m2 or higher with a weight-related comorbidity; the policy's examples are dyslipidemia, hypertension, type 2 diabetes and sleep apnea. Separate routes exist for cardiovascular risk reduction with established cardiovascular disease and for MASH with F2 to F3 fibrosis (injection only)
2. Age: 12 years or older for Wegovy injection; over 16 for Wegovy HD
3. Lifestyle modification: Wegovy must be used as an adjunct to lifestyle modification, which the policy defines by example as dietary or caloric restriction, exercise, behavioral support or a community-based program. The policy does not specify a 3- or 6-month documented failure period; the version of this criterion printed here earlier overstated it
4. No contraindications: No personal or family history of medullary thyroid carcinoma, no MEN2 syndrome, not pregnant or planning pregnancy within 2 months
5. Diabetes: Type 2 diabetes counts as a qualifying comorbidity for Wegovy at BMI 27 or higher. Ozempic for diabetes falls under UnitedHealthcare's separate GLP-1 diabetes policy (effective July 1, 2026), which requires an A1C of 6.5 percent or higher or a fasting glucose of 126 mg/dL or higher and excludes weight-loss use

Documentation requirements:

• Office visit notes documenting the lifestyle modification plan the patient is following alongside Wegovy
• Recorded baseline weight and weights at each follow-up visit
• ICD-10 code for obesity (E66.01 for morbid obesity, E66.9 for obesity unspecified) plus codes for any comorbidities claimed
• Statement that Wegovy is being used as an adjunct to lifestyle modification, in the policy's own words
• Attestation that patient has been counseled on risks, including thyroid C-cell tumor risk

The lifestyle-modification criterion is where denials most often originate, not because the policy demands months of failure but because charts often contain nothing on the subject. "Patient reports trying diet and exercise" is thin. Dated notes that name the diet approach, the exercise plan or the program the patient is enrolled in, with a recorded baseline weight, satisfy the criterion as written and give the renewal review its 5 percent baseline.

The denial pattern: why 40% of requests fail and how to avoid it

Correction, September 2026: an earlier version of this section cited a 2024 American Journal of Managed Care analysis (Chambers et al.) finding a 41 percent denial rate with a percentage breakdown. We could not locate that analysis, and UnitedHealthcare publishes no Wegovy denial rate, so the figures have been removed. The denial reasons below are the criteria the September 1, 2026 policy actually tests:

Denial reason	Percentage of denials	How to prevent
Lifestyle modification not documented	Not published	Provide dated office notes naming the diet, exercise, behavioral or program component and a recorded baseline weight
Missing or incorrect comorbidity coding (BMI 27 to 29.9 patients)	Not published	Include ICD-10 codes for hypertension (I10), type 2 diabetes (E11.9), dyslipidemia (E78.5), OSA (G47.33) with supporting labs or readings
BMI documentation missing or below threshold	Not published	Calculate and document BMI explicitly in the prior auth form; attach recent weight and height measurements
Step therapy not completed	Not published	The September 1, 2026 policy lists no step requirement for Wegovy; if your specific plan adds one, complete the required trial first
Contraindication present	Not published	Screen for MTC and MEN 2 family history and document negative screening

The "insufficient documentation" category is the preventable failure mode. Providers often submit prior authorization requests with a checkbox attestation that lifestyle modification was attempted, but no supporting records. UHC's pharmacy benefit manager reviews the attached clinical notes. If the notes don't explicitly show diet counseling, exercise recommendations, and serial weight measurements, the request is denied.

FormBlends clinical pattern observation: Across the prior authorization requests we review for patients switching to compounded semaglutide after coverage denial, the most common pattern is a primary care visit where the provider discussed weight loss verbally but documented only "counseled on diet and exercise" without specifics. Three months later, the prior auth is filed and denied for lack of evidence. The fix: providers should document the specific diet plan recommended (Mediterranean, low-carb, calorie target), the exercise prescription (150 minutes moderate activity per week, resistance training 2x/week), and the follow-up plan. That documentation satisfies the UHC requirement.

What most articles get wrong about Medicare coverage

The most common error in published content about UnitedHealthcare and Wegovy: conflating Medicare Advantage with Medicare Part D and stating flatly that "Medicare doesn't cover Wegovy."

The correct distinction:

• Traditional Medicare Part D (prescription drug plans, including UHC and AARP-branded plans): The statutory exclusion still bars ordinary Part D coverage of Wegovy for weight loss. But since July 1, 2026 the Medicare GLP-1 Bridge, a CMS program outside the regular benefit, covers the Wegovy pen and pill at a $50 copay per 30-day supply through December 31, 2027 for enrollees with a BMI of 35 or higher, or 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a or worse kidney disease, or 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease (CMS provider page, August 6, 2026). The copay does not count toward the $2,100 Part D cap.

• Medicare Advantage (Part C) plans with drug coverage: follow the same Part D rules, so the route is the same Bridge. Correction, September 2026: the claim printed here earlier that UnitedHealthcare Medicare Advantage plans added Wegovy to most formularies in 2024 as a supplemental benefit could not be verified and has been removed. Under the Bridge the pharmacy submits the prior authorization at the first fill, CMS requires a decision within 72 hours, and there is no appeal, only resubmission.

The distinction no longer decides access. Whether you have a UnitedHealthcare Medicare Advantage plan or traditional Medicare with a standalone UHC or AARP Part D plan, the Bridge criteria are what matter: BMI, the listed conditions, and the absence of type 2 diabetes, moderate to severe sleep apnea or MASH. People excluded from the Bridge use regular Part D routes: Ozempic for diabetes, or Wegovy for cardiovascular risk reduction or MASH where the plan covers those indications.

What comes after the Bridge: The Bridge ends December 31, 2027. The BALANCE model was designed to succeed it, but KFF (May 11, 2026) reports the Part D phase has been delayed indefinitely while the Medicaid phase runs May 1, 2026 to December 31, 2031 at a negotiated $245 per monthly supply. The Treat and Reduce Obesity Act has not passed as of September 5, 2026.

The cost breakdown when coverage is approved

When prior authorization is approved, your out-of-pocket cost depends on your plan's tier structure and deductible status:

Plan type	Typical formulary tier	Copay range (before manufacturer card)	Annual deductible applies?
UHC Commercial (preferred tier)	Tier 3 (preferred brand)	$40 - $80 per month	Often yes
UHC Commercial (non-preferred tier)	Tier 4 (non-preferred brand)	$100 - $200 per month	Yes
UHC Commercial (high-deductible)	Tier 3 or 4	Full cost until deductible met, then tier copay	Yes
UHC or AARP Medicare (Advantage or Part D)	Medicare GLP-1 Bridge, not a formulary tier	$50 per 30-day supply (July 1, 2026 to December 31, 2027)	No; the copay is outside the deductible and the $2,100 cap
UHC Medicaid	State preferred drug list	Nominal copay where the state covers obesity GLP-1s (13 states as of January 2026, fewer since)	No

Deductible consideration: If your plan has a $3,000 annual deductible and you start Wegovy in January, you may pay the plan's full negotiated price (retail with no offer is about $1,639 a month per GoodRx, September 4, 2026) for the first months until the deductible is met, then drop to the tier copay. In that phase Novo Nordisk's $199 self-pay price for a new patient's first two fills is cheaper than running the claim through insurance, though cash payments do not count toward your deductible.

Novo Nordisk savings card: The manufacturer offers a savings card that lowers the copay to as little as $25 a month with maximum savings of $100 per month for commercially insured patients whose plan covers Wegovy (NovoCare eligibility page, seen September 4, 2026). It excludes patients with government insurance (Medicare, Medicaid, TRICARE). Because the savings are capped at $100, the card helps most when your copay is already in the $100 to $125 range; it does not erase a deductible-phase bill.

Copay accumulator programs: Some employer plans, including some administered by UnitedHealthcare, use accumulator or maximizer programs under which the manufacturer's contribution does not count toward your deductible or out-of-pocket maximum. We could not verify the earlier claim that UnitedHealthcare applied accumulators to most commercial plans from 2023, or the $13,500 card maximum, so both have been removed. With the current card's $100 monthly savings cap, the accumulator effect is at most $1,200 a year of deductible credit.

Check your Summary of Benefits for "copay accumulator" or "copay maximizer" language. If present, the savings card provides month-to-month relief but doesn't reduce your total annual cost as much as expected.

The manufacturer savings card: when it works and when UHC blocks it

The Novo Nordisk Wegovy Savings Card lowers the copay to as little as $25 a month with a maximum savings of $100 per month (NovoCare, seen September 4, 2026); the 24-month term printed here earlier is not in the current program terms. Eligibility requirements:

• Commercial insurance (not Medicare, Medicaid, Tricare, or any government program)
• Insurance covers Wegovy (prior authorization approved)
• Pharmacy processes the card as secondary insurance after your primary UHC plan

When it works:

• UHC commercial plans without copay accumulator programs
• Plans where Wegovy is on a preferred tier (Tier 2 or 3)
• Patients who have met their annual deductible

When it doesn't work:

• Medicare Advantage plans (federal anti-kickback statute prohibits manufacturer copay assistance for government insurance)
• Plans with copay accumulator or maximizer programs (card works but doesn't count toward deductible)
• Plans that exclude manufacturer copay cards entirely in the benefits design
• High-deductible health plans before the deductible is met (you pay full cost, not $25, until deductible is satisfied)

The workaround for accumulator programs: Some patients use the savings card for the first 3 to 6 months to access treatment at $25/month, then switch to compounded semaglutide once the card's benefit is exhausted or the deductible resets. This is a common pattern we observe in patients transitioning to FormBlends after their first plan year on brand-name Wegovy.

Step therapy requirements: the medications you must try first

Some UnitedHealthcare plans require step therapy, meaning you must try and fail other weight-loss medications before Wegovy is covered. Step therapy requirements vary by plan, but the most common sequence:

Tier 1 (try first):

• Phentermine (generic appetite suppressant, $10 to $30/month)
• Orlistat (generic Xenical, lipase inhibitor, $50 to $80/month)

Tier 2 (try if Tier 1 fails):

• Contrave (naltrexone/bupropion combination, $100 to $200/month)
• Qsymia (phentermine/topiramate combination, $150 to $250/month)

Tier 3 (GLP-1 agonists):

• Saxenda (liraglutide, daily injection, $1,200+/month)
• Wegovy (semaglutide, weekly injection)

If your plan has step therapy, your provider must document that you tried the Tier 1 medications for at least 8 to 12 weeks each and either did not lose sufficient weight (<5% body weight) or experienced intolerable side effects. The prior authorization form will ask for the specific medications tried, dates of use, and reason for discontinuation.

Step therapy exemption requests: If you have a contraindication to the step therapy medications (for example, uncontrolled hypertension contraindicating phentermine), your provider can request an exemption. UHC reviews exemption requests on a case-by-case basis. UnitedHealthcare does not publish an exemption approval rate; the 60 percent figure and citation printed here earlier could not be verified and have been removed. Note that the September 1, 2026 policy itself lists no step requirement for Wegovy, so step therapy comes from plan-specific design, not the base policy.

The appeal process: a working protocol for overturning denials

If your prior authorization is denied, you have three levels of appeal:

Level 1: Peer-to-peer review (file within 30 days of denial)

Your prescribing provider requests a phone call with a UnitedHealthcare medical director to discuss the case. The medical director is a licensed physician. Your provider presents the clinical rationale, clarifies any missing documentation, and argues for medical necessity.

Success rate: not published. Most successful peer-to-peer reviews involve cases where the initial denial was for administrative reasons (missing documentation) rather than clinical reasons (patient doesn't meet criteria). The percentage printed here earlier came from a citation we could not verify.

Timeline: UHC must schedule the peer-to-peer call within 3 business days for urgent requests, 14 days for standard requests.

Level 2: Internal appeal (file within 60 days of Level 1 denial)

Submit a written appeal with additional supporting documentation. Include:

• Updated clinical notes showing continued lifestyle intervention attempts
• Letters from specialists (endocrinologist, bariatric medicine physician) supporting GLP-1 therapy
• Published studies demonstrating efficacy and safety of semaglutide for obesity (cite STEP 1-4 trials)
• Patient statement describing impact of obesity on quality of life and functional status

Success rate: not published. Most successful internal appeals involve new information not available during the initial review (for example, a new diagnosis of type 2 diabetes or sleep apnea, both named comorbidities in the policy).

Timeline: UHC must respond within 30 days for standard appeals, 72 hours for urgent appeals.

Level 3: External review (file within 60 days of Level 2 denial)

Request an independent review by an external third-party reviewer not affiliated with UHC. This is a federal right under the Affordable Care Act for all non-grandfathered health plans.

Success rate: not published for obesity medications; the 25 to 30 percent figure attributed to the AMA here earlier could not be verified and has been removed. External reviewers are more likely to overturn denials when the patient clearly meets the plan's written criteria but the insurer applied a stricter interpretation.

Timeline: The external reviewer must issue a decision within 60 days.

The practical reality: Most patients who are denied coverage do not complete all three appeal levels. The process takes 3 to 6 months total. Many patients switch to compounded semaglutide during the appeal process to avoid treatment interruption. If the appeal is successful, they can switch back to brand-name Wegovy.

Compounded semaglutide as the coverage alternative

When UnitedHealthcare denies Wegovy coverage or the out-of-pocket cost is prohibitive, compounded semaglutide is the most common alternative. Key differences:

Feature	Brand Wegovy	Compounded semaglutide
FDA approval	Yes (approved 2021)	No (compounded under 503A/503B exemptions)
Insurance coverage	Possible with prior auth	Not covered by insurance
Cost (September 2026)	About $1,639 retail with no offer; $199 for two fills then $349 self-pay via NovoCare; as little as $25 with the savings card; $50 on Medicare's Bridge	$197 month-one median, $224 month-four median across 14 telehealth providers (FormBlends price index, September 3, 2026); FormBlends' own price is on the product page
Dosing	Pre-filled single-dose pen	Multi-dose vial requiring manual injection
Active ingredient	Semaglutide base	Semaglutide base or semaglutide sodium salt
Availability	Shortage declared resolved by FDA on February 21, 2025; pen and pill both available; NovoCare notes no insurance coverage yet for Wegovy HD 7.2 mg	Widely available from 503A pharmacies on individual prescriptions; not FDA-approved; FDA logged 990 adverse-event reports for compounded semaglutide as of May 31, 2026

Compounded semaglutide is not FDA-approved and has not undergone the same review process as Wegovy. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. The active ingredient is the same, but the formulation, excipients, and delivery method differ.

When compounded semaglutide makes sense:

• UHC denied coverage and appeals failed or are pending
• Out-of-pocket cost with insurance exceeds $300/month
• Patient is on a high-deductible plan and hasn't met the deductible
• Patient has traditional Medicare Part D (no Wegovy coverage possible)

When brand Wegovy makes sense:

• Insurance covers it with a copay under $100/month
• Patient prefers the convenience of a pre-filled pen
• Patient wants FDA-approved medication

The clinical outcomes data for compounded semaglutide is limited compared to the published STEP trials for Wegovy, but the pharmacokinetics of semaglutide base are well-established. Patients switching from Wegovy to compounded semaglutide at equivalent doses report similar efficacy and side effect profiles in observational data (though no head-to-head RCTs exist).

Internal link: For a detailed comparison of brand vs compounded options, see our guide at /articles/general-glp1/wegovy-vs-compounded-semaglutide-cost-coverage-comparison/.

When to expect policy changes: the 2027 Medicare coverage expansion

Correction, September 2026: this section predicted 2027 changes. One of them arrived early in a different form, and the other has not happened. Here is the current state:

1. Medicare Part D coverage via TROA

The Treat and Reduce Obesity Act would eliminate the statutory exclusion preventing Medicare Part D from covering weight-loss medications. It has not passed as of September 5, 2026, and we no longer print cosponsor counts. Instead, CMS used demonstration authority: the Medicare GLP-1 Bridge began July 1, 2026 and runs through December 31, 2027.

The Bridge's criteria are stricter than UnitedHealthcare's commercial policy: BMI 35 or higher on its own, or 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a or worse kidney disease, or 27 or higher with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. Type 2 diabetes, moderate to severe sleep apnea and MASH patients are excluded (CMS, August 6, 2026).

What replaces the prediction: The Bridge ends December 31, 2027. Its intended successor, the BALANCE model, has a Medicaid phase running May 1, 2026 to December 31, 2031 at a negotiated $245 per monthly supply, while the Part D phase has been delayed indefinitely (KFF, May 11, 2026). Whether Medicare coverage of Wegovy continues into 2028 is an open question as of September 2026.

2. Expanded Medicare Advantage formulary inclusion

Correction, September 2026: the 75 percent formulary figure printed here earlier could not be verified and has been removed. For obesity, Medicare Advantage formularies are now beside the point: the Bridge applies to every Part D enrollee who meets its criteria, regardless of which UnitedHealthcare or AARP plan they hold. Medicare Advantage plans still compete on formulary design for the other Wegovy indications during open enrollment (October 15 to December 7).

UnitedHealthcare's 2027 formularies will be published in October 2026. We make no prediction about tier placement; check the plan's 2027 formulary document and the CMS Bridge page when they are released.

UnitedHealthcare's Wegovy criteria, effective September 1, 2026, quoted

UnitedHealthcare publishes its pharmacy prior authorization policy for weight-loss drugs as a public PDF. The version effective September 1, 2026 supersedes everything paraphrased in earlier versions of this article.

UnitedHealthcare weight-loss PA policy, effective September 1, 2026	Wegovy criterion
Covered indications	Appetite suppression or weight loss; risk reduction of major adverse cardiovascular events with established cardiovascular disease (injection or tablet); MASH with F2 to F3 fibrosis (injection only)
Age	12 or older for Wegovy injection; over 16 for Wegovy HD
Lifestyle	Used as an adjunct to lifestyle modification (dietary or caloric restriction, exercise, behavioral support, community-based program)
BMI	30 kg/m2 or higher (pediatric: above the 95th percentile), or 27 kg/m2 or higher with a weight-related comorbidity such as dyslipidemia, hypertension, type 2 diabetes or sleep apnea; not required for the MASH route
Initial authorization	5 months for Wegovy injection, tablet and HD (6 months for Zepbound, 4 months for Contrave)
Reauthorization	Weight loss of at least 5 percent of baseline body weight plus continued lifestyle modification, then 12 months; MASH route renews on documented clinical response without cirrhosis
Plans excluding weight-loss drugs	Separate nonformulary Wegovy criteria apply
State variations	State mandates may apply; North Dakota small-group and individual EHB plans require BMI 40 or higher or MASH

The policy's revision history shows how quickly it moves: the Wegovy initial authorization was cut to 5 months in May 2025, MASH was added in November 2025, the tablet was added in February 2026 and Wegovy HD in May 2026. Read the current PDF before relying on any summary, including this one.

Which UHC plan types require PA, and which are decided elsewhere

UnitedHealthcare plan type	Wegovy prior authorization	Source
Commercial HMO, PPO and employer plans	Required (policy effective September 1, 2026)	UHC PA notification; PrescriberPoint
Exchange (ACA) HMO and PPO	PrescriberPoint lists no PA; coverage of weight-loss drugs on exchange plans is rare (1 percent of Marketplace plans covered Wegovy or Saxenda in 2024 per healthinsurance.org)	PrescriberPoint, seen September 5, 2026
Medicare Advantage with Part D	Bridge prior authorization at the first fill	CMS, August 6, 2026
Standalone Part D (UHC, AARP)	Bridge prior authorization at the first fill; PrescriberPoint lists PA plus quantity limit for other indications	CMS; PrescriberPoint
Self-funded employer plans	Employer decides whether weight-loss drugs are covered at all; 67 percent of covered workers are in such plans (KFF, October 22, 2025)	KFF EHBS 2025

The single most useful step is to find your plan's Prescription Drug List on uhc.com and search for Wegovy. If it is not listed, the employer excluded weight-loss drugs and the policy's nonformulary criteria, not the standard ones, govern any exception request.

UHC and AARP Medicare members: Wegovy for $50 under the GLP-1 Bridge (July 1, 2026 to December 31, 2027)

UnitedHealthcare is the largest Medicare Advantage carrier and, through AARP-branded plans, a major Part D carrier, so this section replaces the earlier Medicare discussion entirely.

Bridge rule (CMS, last updated August 6, 2026)	Detail
Dates	July 1, 2026 through December 31, 2027
Copay	$50 per 30-day supply; the copay does not count toward the Part D deductible or the $2,100 out-of-pocket cap
Drugs	Wegovy pen and pill, Zepbound KwikPen only (not single-dose pens or vials), Foundayo
Who qualifies	BMI 35 or higher; or BMI 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or worse; or BMI 27 or higher with prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease
Who is excluded	People with type 2 diabetes, moderate to severe obstructive sleep apnea, or MASH use regular Part D coverage instead
Prior authorization	Pharmacy transmits the request within 24 to 72 hours; decision within 72 hours; no appeals, but a corrected request can be resubmitted; approval is valid through December 31, 2027 for refills and dose changes

Novo Nordisk's NovoCare page confirms the $50 Bridge copay is available nationwide from July 1, 2026 through the end of 2027. If you are excluded from the Bridge because you have type 2 diabetes, Ozempic under your plan's regular Part D formulary is the semaglutide route; UnitedHealthcare's GLP-1 diabetes policy for commercial plans (effective July 1, 2026) shows the shape of such a review: A1C 6.5 percent or higher or fasting glucose 126 or higher, 12-month authorization.

Why your employer may have opted out: UnitedHealthcare's own numbers

UnitedHealthcare's article for employers and brokers, published March 30, 2026, is unusually frank about why self-funded plans exclude weight-loss GLP-1s.

UnitedHealthcare employer-facing data (March 30, 2026)	Figure
GLP-1 spending growth 2018 to 2023	More than 500 percent, from a $13.7 billion base
Average GLP-1 cost	More than $1,000 per patient per month
Per-member-per-month cost change in the 12 months after a GLP-1 start	91 percent increase versus the 12 months before
Patients who stop before a clinically meaningful benefit	58 percent
UHC members with a metabolic condition in 2023	28 percent

The employer surveys point the same way. KFF (October 22, 2025) found only 16 percent of firms with 200 to 999 workers, 30 percent with 1,000 to 4,999 and 43 percent with 5,000 or more cover GLP-1s for weight loss; a 2026 survey of 307 employers reported by healthinsurance.org (August 20, 2026) found 36 percent cover weight loss and 5 to 10 percent of those plan to drop it in 2027. Blue Cross Blue Shield of Massachusetts excluded Wegovy, Saxenda and Zepbound from plans renewing on or after January 1, 2026. If your UnitedHealthcare card comes from a self-funded employer, this is the decision that determines your answer.

What you pay when UHC covers Wegovy, and when it does not

Situation (checked September 4 to 5, 2026)	Monthly cost	Source
Commercial plan covers Wegovy, savings card applied	As little as $25; maximum savings $100 a month	NovoCare eligibility page
Commercial plan covers Wegovy, deductible not met	Plan's negotiated price until the deductible is met (retail with no offer is about $1,639)	GoodRx via wegovy.com
Plan excludes Wegovy: NovoCare self-pay pen	$199 a month for a new patient's first two fills (through December 31, 2026), then $349	wegovy.com
Wegovy HD 7.2 mg	$399 self-pay; no insurance coverage available yet	NovoCare coverage page
Wegovy pill	$149 (1.5 mg), $199 (4 mg after August 31, 2026), $299 (higher strengths)	wegovy.com
UHC or AARP Medicare, Bridge criteria met	$50 per 30-day supply	CMS; Medicare.gov
Compounded semaglutide, 14-provider median	$197 month one (range $88 to $299); $224 month four; not FDA-approved	FormBlends price index, September 3, 2026
FormBlends compounded semaglutide (our own row)	Current price on the product page and in our price index	Same index rules as every other provider

For a patient whose employer excludes Wegovy, the manufacturer's own $199 then $349 price now competes directly with compounded semaglutide in the Compounded GLP-1 Price Index; the compounded median is lower from month three, but compounded products are not FDA-approved and FDA counted 990 adverse-event reports for compounded semaglutide as of May 31, 2026.

Wegovy pill and Wegovy 1.5 mg: what UnitedHealthcare's policy says

Readers arriving here for "wegovy 1.5 mg" are usually asking about the oral tablet, whose starting strength is 1.5 mg. UnitedHealthcare's September 1, 2026 policy lists "Wegovy (semaglutide) tablet" alongside the injection under the same criteria and the same 5-month initial authorization, with a footnote that the tablet, like Foundayo, may sit in an Exclude at Launch status on some formularies until the plan adds it. The tablet qualifies for the weight-loss and cardiovascular indications but not the MASH route, which is injection only. Self-pay through NovoCare Pharmacy is $149 a month for 1.5 mg, $199 for 4 mg (a price that took effect after August 31, 2026) and $299 for higher strengths (wegovy.com, seen September 4, 2026). Medicare's GLP-1 Bridge covers the pill at the same $50 as the pen. The 7.2 mg Wegovy HD injection is the opposite case: on the policy, but NovoCare says no insurance coverage is available for it yet, so its $399 self-pay price is the practical price.

FAQ

Does UnitedHealthcare cover Wegovy for weight loss?

Yes on commercial plans whose employer includes weight-loss drugs, with prior authorization. UnitedHealthcare's policy effective September 1, 2026 requires age 12 or older, a BMI of 30 or higher or 27 with a comorbidity such as dyslipidemia, hypertension, type 2 diabetes or sleep apnea, and use alongside lifestyle modification; it does not require months of documented failure. Approval is 5 months, renewable at 5 percent weight loss. Medicare members can use the $50 GLP-1 Bridge since July 1, 2026.

How much does Wegovy cost with UnitedHealthcare insurance?

It depends on your tier and deductible. With commercial coverage the Novo Nordisk savings card lowers the copay to as little as $25 a month with a maximum savings of $100 per month (NovoCare, September 4, 2026); it is not available with Medicare or Medicaid. Medicare members pay $50 a month through the GLP-1 Bridge if eligible. Without coverage, NovoCare self-pay is $199 for a new patient's first two pen fills then $349, $399 for Wegovy HD, and $149 to $299 for the pill.

Why was my Wegovy prior authorization denied by UnitedHealthcare?

The criteria UnitedHealthcare's September 1, 2026 policy tests are a documented BMI of 30 or higher (or 27 with a coded comorbidity supported by labs or readings), use as an adjunct to lifestyle modification, age 12 or older, and a covered indication. Denials usually trace to one of those being missing from the chart, or to an employer plan that excludes weight-loss drugs. UnitedHealthcare publishes no denial breakdown; the percentages printed here earlier were unsourced and have been removed.

Does UnitedHealthcare Medicare Advantage cover Wegovy?

Since July 1, 2026, yes, through the Medicare GLP-1 Bridge rather than the plan formulary: the Wegovy pen or pill costs $50 a month through December 31, 2027 for enrollees with a BMI of 35 or higher, or 30 or 27 with specific conditions, excluding people with type 2 diabetes, sleep apnea or MASH (CMS, August 6, 2026). The pharmacy submits prior authorization at the first fill and CMS decides within 72 hours. The 2024 formulary claim printed here earlier could not be verified.

Does Medicare Part D cover Wegovy?

Not through the ordinary Part D benefit, which the Social Security Act still bars from covering weight-loss drugs. But since July 1, 2026 every Part D enrollee, in a standalone UHC or AARP drug plan or a Medicare Advantage plan, can get the Wegovy pen or pill for $50 a month through the Medicare GLP-1 Bridge if they meet its BMI criteria and do not have type 2 diabetes, moderate to severe sleep apnea or MASH (Medicare.gov; CMS, August 6, 2026).

What is the prior authorization process for Wegovy with UnitedHealthcare?

Your provider submits a prior authorization documenting your BMI (30 or higher, or 27 with a comorbidity), your age (12 or older), the lifestyle modification plan Wegovy accompanies, and the indication, per the policy effective September 1, 2026. Approval lasts 5 months; renewal for 12 months requires documented weight loss of at least 5 percent of baseline and continued lifestyle modification. Novo Nordisk says a PA can take up to 10 business days.

Can I appeal a UnitedHealthcare Wegovy denial?

Yes. You have three levels: a peer-to-peer review between your prescriber and a UnitedHealthcare medical director, an internal written appeal with new documentation, and an external independent review guaranteed under the Affordable Care Act. UnitedHealthcare publishes no success rates, and the percentages printed here earlier have been removed. The full process can take months; many patients use Novo Nordisk's $199 self-pay price or compounded semaglutide in the meantime.

Does the Wegovy savings card work with UnitedHealthcare?

Yes, for commercial plans that cover Wegovy. The Novo Nordisk savings card lowers your copay to as little as $25 a month with a maximum savings of $100 per month (NovoCare, seen September 4, 2026); the 24-month term printed here earlier is not in the current terms. It does not work with Medicare, Medicaid or other government insurance. Some employer plans use accumulator programs that keep the card's value from counting toward your deductible.

What weight-loss medications does UnitedHealthcare require me to try before Wegovy?

Some plans require step therapy, meaning you must try phentermine, orlistat, Contrave, or Qsymia first. Requirements vary by plan. Your provider can request a step therapy exemption if you have contraindications to the required medications.

How long does UnitedHealthcare prior authorization take for Wegovy?

UnitedHealthcare's weight-loss policy does not state a turnaround time. Novo Nordisk's NovoCare coverage page says a Wegovy prior authorization can take up to 10 business days, which is the best public benchmark. For Medicare's GLP-1 Bridge, CMS says the pharmacy transmits the request within 24 to 72 hours and the decision comes within 72 hours. Ask your plan for its written standard and urgent review timelines.

What happens if I lose weight on Wegovy and my BMI drops below 30?

Losing weight is the point, and the policy rewards it: under UnitedHealthcare's criteria effective September 1, 2026, the initial 5-month approval is renewed for 12 months when you have lost at least 5 percent of your baseline body weight and continue lifestyle modification. A BMI that drops below 30 during treatment does not end coverage; failing to reach 5 percent weight loss by the renewal review can. An earlier version of this answer said renewal was not required; that was wrong.

Can I get Wegovy covered for prediabetes with UnitedHealthcare?

Possibly. UnitedHealthcare's September 1, 2026 policy requires a weight-related comorbidity at a BMI of 27 to 29.9 and gives dyslipidemia, hypertension, type 2 diabetes and sleep apnea as examples; prediabetes is not named, so acceptance depends on the reviewer. Document it with labs (A1C 5.7 to 6.4 percent or fasting glucose 100 to 125 mg/dL). Medicare's GLP-1 Bridge does explicitly accept prediabetes at a BMI of 27 or higher.

Does UnitedHealthcare cover the Wegovy pill?

Under the policy effective September 1, 2026, Wegovy tablet is covered with prior authorization on the same terms as the injection: age 12 or older, BMI 30 or higher or 27 with a comorbidity, use alongside lifestyle modification, 5-month initial approval and renewal at 5 percent weight loss. The policy notes the tablet may be in Exclude at Launch status on some formularies, so check your plan's drug list. Self-pay is $149, $199 or $299 by strength (NovoCare, September 4, 2026).

Does AARP UnitedHealthcare Medicare cover Wegovy?

Since July 1, 2026, yes, through the Medicare GLP-1 Bridge rather than the AARP plan's own formulary: the Wegovy pen or pill costs $50 per 30-day supply through December 31, 2027 for Part D enrollees with a BMI of 35 or higher, or 30 or 27 with specific conditions, excluding anyone with type 2 diabetes, moderate to severe sleep apnea or MASH (CMS, August 6, 2026). The pharmacy submits prior authorization at the first fill; the copay does not count toward the $2,100 Part D cap.

What is UnitedHealthcare's reauthorization requirement for Wegovy?

After the initial 5-month authorization, UnitedHealthcare's policy effective September 1, 2026 renews Wegovy injection, tablet or HD for 12 months only if you have lost at least 5 percent of your baseline body weight and are continuing lifestyle modification. For the MASH indication the renewal test is a documented clinical response, such as improved or stable fibrosis, without progression to cirrhosis. Keep dated baseline and follow-up weights from the first fill onward.

Does UnitedHealthcare Choice Plus cover Wegovy?

Choice Plus is a UnitedHealthcare network and plan design sold to employers, not a single formulary, so the answer depends on whether your employer included weight-loss drugs in its pharmacy benefit. If it did, the September 1, 2026 prior authorization criteria apply (BMI 30 or 27 with a comorbidity, lifestyle modification, 5-month approval). If it did not, the policy's nonformulary Wegovy criteria govern any exception. Search your plan's Prescription Drug List on uhc.com for Wegovy to find out which case you are in.

Related guides

• Does UnitedHealthcare Cover Wegovy? The 2026 Policy Breakdown and What to Do If You're Denied
• Will Cigna Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and What to Do When Denied
• Does Blue Cross Blue Shield Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and What to Do When Denied
• Does Medica Cover Wegovy for Weight Loss? 2026 Policy Breakdown and What to Do If Denied
• Does UnitedHealthcare Cover Weight Loss Injections? The 2026 Policy Reality and What to Do When Denied
• Does Medical Mutual Cover Weight Loss Medication? The 2026 Policy Breakdown and What to Do When Coverage Is Denied

Sources

1. Removed September 2026: an AJMC denial-pattern analysis (Chambers et al., 2024) cited here earlier could not be located; the denial and appeal percentages attributed to it have been deleted.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 trial). JAMA. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4 trial). JAMA. 2021.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 trial). Lancet. 2021.
6. UnitedHealthcare. Prior authorization notification: diabetes agents, GLP-1 receptor agonists, effective July 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/a-g/PA-Notification-Diabetes-Agents-GLP1-Receptor-Agonists.pdf
7. Social Security Act Section 1862(a)(1)(A). Exclusion of certain items and services from Medicare coverage. 42 U.S.C. § 1395y.
8. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. Updated 2025.
9. Novo Nordisk. Wegovy Prescribing Information. Updated December 2025.
10. Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge, information for providers, last updated August 6, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
11. UnitedHealthcare. Pharmacy prior authorization notification: weight loss, effective September 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf
12. KFF. What to know about the BALANCE model for GLP-1s in Medicare and Medicaid, May 11, 2026. https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
13. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
14. Academy of Nutrition and Dietetics. Position Paper: Weight Management. Journal of the Academy of Nutrition and Dietetics. 2024.
15. UnitedHealthcare. Pharmacy prior authorization notification: weight loss (Wegovy, Zepbound, Contrave and others), effective September 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf
16. UnitedHealthcare. Prior authorization notification: diabetes agents, GLP-1 receptor agonists (A1C 6.5 percent or fasting glucose 126, 12-month authorization), effective July 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/a-g/PA-Notification-Diabetes-Agents-GLP1-Receptor-Agonists.pdf
17. UnitedHealthcare. Prescription drug lists (check your plan's PDL), seen September 5, 2026. https://www.uhc.com/member-resources/pharmacy-benefits/prescription-drug-lists
18. PrescriberPoint. Wegovy coverage on UnitedHealthcare plans (plan-type matrix), seen September 5, 2026. https://prescriberpoint.com/therapies/wegovy-ee06186/coverage/unitedhealthcare-uhc
19. UnitedHealthcare. Demand for GLP-1 drugs: what employers should know (91 percent per-member-per-month cost increase; 58 percent discontinue before meaningful benefit), March 30, 2026. https://www.uhc.com/agents-brokers/employer-sponsored-plans/news-strategies/demand-for-glp-1-drugs
20. Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge: information for providers (July 1, 2026 to December 31, 2027; Wegovy, Zepbound KwikPen, Foundayo; BMI criteria; 72-hour decisions), last updated August 6, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
21. Medicare.gov. Weight-loss drug coverage and the Medicare GLP-1 Bridge ($50 monthly copay, does not count toward deductible or out-of-pocket limits), seen September 5, 2026. https://www.medicare.gov/coverage/weight-loss-drugs
22. KFF. What to know about the BALANCE model for GLP-1s in Medicare and Medicaid, May 11, 2026. https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
23. Novo Nordisk. What to pay for Wegovy (self-pay pen $199 for the first two fills then $349, Wegovy HD $399, pill $149, $199, $299; savings card $25 with $100 monthly maximum), seen September 4, 2026. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
24. Novo Nordisk, NovoCare. Check your Wegovy coverage (prior authorization can take up to 10 business days; no insurance coverage yet for Wegovy 7.2 mg; Medicare GLP-1 Bridge $50), seen September 5, 2026. https://www.novocare.com/patient/medicines/wegovy/check-coverage.html
25. Novo Nordisk, NovoCare. Wegovy savings card eligibility ($25 with coverage, $100 a month maximum savings), seen September 4, 2026. https://www.novocare.com/eligibility/wegovy-savings-card.html
26. KFF. 2025 Employer Health Benefits Survey (GLP-1 weight-loss coverage by firm size; 67 percent of covered workers in self-funded plans), October 22, 2025. https://www.kff.org/health-costs/2025-employer-health-benefits-survey/
27. healthinsurance.org. Does health insurance cover drugs used for weight loss such as Ozempic, Wegovy, Mounjaro and Zepbound? (employer survey, Medicaid exits, Marketplace data), updated August 20, 2026. https://www.healthinsurance.org/faqs/does-health-insurance-cover-drugs-used-for-weight-loss-such-as-ozempic-wegovy-mounjaro-and-zepbound/
28. KFF. Medicaid coverage of and spending on GLP-1s (13 states covered obesity use as of January 2026), January 2026. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
29. Penn LDI. Patients face new barriers for GLP-1 drugs like Wegovy and Ozempic (summary of Klebanoff et al., JAMA, September 25, 2025), January 21, 2026. https://ldi.upenn.edu/our-work/research-updates/patients-face-new-barriers-for-glp-1-drugs-like-wegovy-and-ozempic/
30. FormBlends. Compounded GLP-1 Price Index methodology and current medians, data as of September 3, 2026. https://formblends.com/report/data/compounded-glp1-price-index

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. UnitedHealthcare, UHC, and Oxford are registered trademarks of UnitedHealth Group. Medicare and Medicaid are federal programs administered by the Centers for Medicare & Medicaid Services. Saxenda is a registered trademark of Novo Nordisk. Contrave is a registered trademark of Currax Pharmaceuticals. Qsymia is a registered trademark of Vivus Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies or government agencies.